Compass Pathways (NASDAQ:CMPS) today reported its financial results for the fourth quarter and full year ended December 31, 2025, revealing a disciplined fiscal year characterized by strategic cost management and a significantly extended capital runway.
The mental health care company reported that its current cash position is expected to fund operating expenses and capital requirements into 2028, a critical window that covers the anticipated primary data readouts for its pivotal COMP360 Phase 3 program in treatment-resistant depression (TRD).
The company’s research and development (R&D) expenses for the full year 2025 remained broadly stable at $118.4 million, compared with $119 million in 2024.
For the fourth quarter specifically, R&D spend decreased to $29.9 million, down from $32.1 million in the prior year period.
This reduction is largely attributed to the personnel and share-based compensation savings realized from the corporate reorganization executed in late 2024.
General and administrative (G&A) expenses for the year were $60.6 million, up slightly from $59.2 million in 2024, primarily due to legal and professional fees associated with the company's January 2025 financing round.
A notable feature of the 2025 report was the significant variability in net loss driven by non-cash accounting adjustments.
The full-year net loss was $287.9 million ($3.08 per share), compared to $155.1 million in 2024.
However, this increase was primarily fueled by a $122.6 million non-cash loss on the fair value adjustment of warrant liabilities.
As these warrants fluctuate with the company’s share price and other market inputs, they can create substantial "paper" volatility that does not reflect the company’s actual operational cash burn or clinical progress.
As of December 31, 2025, Compass Pathways held $149.6 million in cash and cash equivalents.
Crucially, as of March 24, 2026, the company’s debt stood at $50.4 million, reflecting a strategic balance of non-dilutive capital alongside its equity reserves.